A cost-effective innovation in anaemia management for paediatric patients with haemodialysis-dependent chronic kidney disease
This study underscores the clinical efficacy and economic benefits of ferric carboxymaltose as a viable treatment for iron deficiency anaemia in paediatric patients who are haemodialysis-dependent and highlights the potential for significant improvements in healthcare delivery, in terms of reducing frequency of hospital visits for this patient population.
Authors
- Rebecca Preston (ORCID: https://orcid.org/0000-0002-3971-6028)
- Demetria Theodorou
- Kate Sinnott
- Dean Wallace
- Amrit Kaur (ORCID: https://orcid.org/0000-0001-7732-4001)
Institutions
- Manchester Academic Health Science Centre (GB)
- Wellcome Centre for Cell-Matrix Research (GB)
- University of Manchester (GB)
- Royal Manchester Children's Hospital (GB)
Publication Details
- Journal
- Pediatric Nephrology
- Published
- 2025-03-01
- DOI
- https://doi.org/10.1007/s00467-025-06680-x
- Primary Topic
- Iron Metabolism and Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00